Skip to main content
SpringerLink
Log in

Impact of Exogenous Melatonin on Sleep and Daytime Functioning in Healthy, Typically Developing Adolescents

  • Sleep and Development (L Tarokh, Section Editor)
  • Published:
Current Sleep Medicine Reports Aims and scope Submit manuscript

Abstract 

Purpose of Review

Use of exogenous melatonin as a sleep aid is steadily increasing among youth. Despite limited understanding regarding the acute and long-term effects on circadian timing, sleep, and daytime functioning, melatonin is recommended to adolescents for sleep difficulties more than any other age group. This review summarizes and synthesizes the most recent research examining the efficacy of melatonin treatment on sleep difficulties in healthy, typically developing adolescents.

Recent Findings

Research allowing for cause-effect inferences on the effects of melatonin treatment in typically developing adolescents is quite limited. However, the literature that exists suggests that melatonin administration through adolescence appears effective and without observed untoward effects.

Summary

Clinical use of melatonin should be well considered and aligned appropriately with diagnoses. There is a critical need for longitudinal and experimental research aimed at better understanding the effects of melatonin on objective and subjective sleep, daytime functioning, and adverse effects in adolescents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References 

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Crowley SJ, Wolfson AR, Tarokh L, Carskadon MA. An update on adolescent sleep: new evidence informing the perfect storm model. J Adolesc. 2018;67:55–65.

    Article  Google Scholar 

  2. Carter KA, Hathaway NE, Lettieri CF. Common sleep disorders in children. Am Fam Physician. 2014;89(5):368–77.

    Google Scholar 

  3. Owens J. Classification and epidemiology of childhood sleep disorders. Primary Care: Clinics in Office Practice. 2008;35(3):533–46.

    Article  Google Scholar 

  4. Wheaton AG, Olsen EOM, Miller GF, Croft JB. Sleep duration and injury-related risk behaviors among high school students—United States, 2007–2013. Morb Mortal Wkly Rep. 2016;65(13):337–41.

    Article  Google Scholar 

  5. Paruthi S, Brooks LJ, D’Ambrosio C, Hall WA, Kotagal S, Lloyd RM, et al. Recommended amount of sleep for pediatric populations: a consensus statement of the American Academy of Sleep Medicine. J Clin Sleep Med. 2016;12(6):785–6.

    Article  Google Scholar 

  6. Bowers JM, Moyer A. Effects of school start time on students’ sleep duration, daytime sleepiness, and attendance: a meta-analysis. Sleep Health. 2017;3(6):423–31.

    Article  Google Scholar 

  7. Ranum BM, Wichstrøm L, Pallesen S, Steinsbekk S. Prevalence and stability of insufficient sleep measured by actigraphy: a prospective community study. Pediatric Research. 2020:1–7.

  8. Cirelli C, Tononi G, editors. The sleeping brain. Cerebrum: the Dana forum on brain science; 2017: Dana Foundation.

  9. Medicine AAoS. International classification of sleep disorders. Diagnostic and coding manual. 2014;3rd edition.

  10. Hysing M, Harvey AG, Linton SJ, Askeland KG, Sivertsen B. Sleep and academic performance in later adolescence: results from a large population-based study. J Sleep Res. 2016;25(3):318–24.

    Article  Google Scholar 

  11. Lee YJ, Park J, Kim S, Cho S-J, Kim SJ. Academic performance among adolescents with behaviorally induced insufficient sleep syndrome. J Clin Sleep Med. 2015;11(01):61–8.

    Article  Google Scholar 

  12. Sivertsen B, Glozier N, Harvey AG, Hysing M. Academic performance in adolescents with delayed sleep phase. Sleep Med. 2015;16(9):1084–90.

    Article  Google Scholar 

  13. Blake MJ, Allen NB. Prevention of internalizing disorders and suicide via adolescent sleep interventions. Curr Opin Psychol. 2020;34:37–42.

    Article  Google Scholar 

  14. Short MA, Bartel K, Carskadon MA. Sleep and mental health in children and adolescents. Sleep and Health: Elsevier; 2019. p. 435–45.

    Google Scholar 

  15. Carson V, Tremblay MS, Chaput J-P, Chastin SF. Associations between sleep duration, sedentary time, physical activity, and health indicators among Canadian children and youth using compositional analyses. Appl Physiol Nutr Metab. 2016;41(6):S294–302.

    Article  Google Scholar 

  16. Hart CN, Jelalian E, Raynor HA. Behavioral and social routines and biological rhythms in prevention and treatment of pediatric obesity. Am Psychol. 2020;75(2):152.

    Article  Google Scholar 

  17. Meltzer LJ, Wainer A, Engstrom E, Pepa L, Mindell JA. Seeing the whole elephant: a scoping review of behavioral treatments for pediatric insomnia. Sleep Med Rev. 2021;56:101410.

    Article  Google Scholar 

  18. Meltzer LJ, Mindell JA. Systematic review and meta-analysis of behavioral interventions for pediatric insomnia. J Pediatr Psychol. 2014;39(8):932–48.

    Article  Google Scholar 

  19. Gradisar M, Dohnt H, Gardner G, Paine S, Starkey K, Menne A, et al. A randomized controlled trial of cognitive-behavior therapy plus bright light therapy for adolescent delayed sleep phase disorder. Sleep. 2011;34(12):1671–80.

    Article  Google Scholar 

  20. Feder MA, Baroni A. Just let me sleep in: identifying and treating delayed sleep phase disorder in adolescents. Child and Adolescent Psychiatric Clinics. 2021;30(1):159–74.

    Article  Google Scholar 

  21. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD, Physicians* CGCotACo. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of internal medicine. 2016;165(2):125–33.

    Article  Google Scholar 

  22. Morgenthaler TI, Lee-Chiong T, Alessi C, Friedman L, Aurora RN, Boehlecke B, et al. Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. Sleep. 2007;30(11):1445–59.

    Article  Google Scholar 

  23. Meltzer LJ, Plaufcan MR, Thomas JH, Mindell JA. Sleep problems and sleep disorders in pediatric primary care: treatment recommendations, persistence, and health care utilization. J Clin Sleep Med. 2014;10(4):421–6.

    Article  Google Scholar 

  24. Thomas A, Grandner M, Nowakowski S, Nesom G, Corbitt C, Perlis ML. Where are the behavioral sleep medicine providers and where are they needed? A geographic assessment Behavioral sleep medicine. 2016;14(6):687–98.

    Article  Google Scholar 

  25. Owens JA, Mindell JA. Pediatric insomnia. Pediatr Clin. 2011;58(3):555–69.

    Google Scholar 

  26. Mindell JA, Kuhn B, Lewin DS, Meltzer LJ, Sadeh A. Sleep AAo Behavioral treatment of bedtime problems and night wakings in infants and young children. Sleep. 2006;29(10):1263–76.

    Google Scholar 

  27. Bartlett DJ, Biggs SN, Armstrong SM. Circadian rhythm disorders among adolescents: assessment and treatment options. Med J Aust. 2013;199:S16–20.

    Article  Google Scholar 

  28. Owens JA, Rosen CL, Mindell JA, Kirchner HL. Use of pharmacotherapy for insomnia in child psychiatry practice: a national survey. Sleep Med. 2010;11(7):692–700.

    Article  Google Scholar 

  29. Black LI, Clarke TC, Barnes PM, Stussman BJ, Nahin RL. Use of complementary health approaches among children aged 4–17 years in the United States: National Health Interview Survey, 2007–2012. Natl Health Stat Rep. 2015;78:1.

    Google Scholar 

  30. Heussler H, Chan P, Price AM, Waters K, Davey MJ, Hiscock H. Pharmacological and non-pharmacological management of sleep disturbance in children: an Australian Paediatric Research Network survey. Sleep Med. 2013;14(2):189–94.

    Article  Google Scholar 

  31. Owens JA, Rosen CL, Mindell JA. Medication use in the treatment of pediatric insomnia: results of a survey of community-based pediatricians. Pediatrics. 2003;111(5):e628–35.

    Article  Google Scholar 

  32. • Kimland EE, Bardage C, Collin J, Järleborg A, Ljung R, Iliadou AN. Pediatric use of prescribed melatonin in Sweden 2006–2017: a register based study. Eur Child Adolesc Psychiatry. 2021;30(9):1339–50. (This paper characterized the prevalence melatonin prescriptions, long-term treatment, psychiatric comorbidities, and adjuvant psychotropic medication prescriptions in children ages 0 to 17 from 2006 to 2017 in Sweden. This study highlighted a significant increase in melatonin use in adolescent girls and boys. Almost 80% of childern had a mental or behavioral disorder, with the most common comorbidity being Attention Deficit Hyperactivity Disorder. Many of the adolescents were treated with multiple medications in addition to melatonin.)

    Article  Google Scholar 

  33. • Procaccini D. Kudchadkar S (2021) P0557/# 1791 Characterization of melatonin use in a large children’s hospital. Pediatric Critical Care Medicine. 2021;22(1):277–8. (This paper characterized melatonin prescribing practices of a tertiary care children's hospital for pediatric inpatients. Melatonin administration within the intensive care unit (ICU) and non-ICU was evenly distributed, with most administration occuring at night for potential sleep regulation. Overall use of melatonin increased 481.8% between 2016 and 2019. The average age of children receiving melatonin was 12.7 years old (SD = 6.2 years).)

  34. • Skrzelowski M, Brookhaus A, Shea LA, Berlau DJ. Melatonin use in pediatrics: evaluating the discrepancy in evidence based on country and regulations regarding production. The Journal of Pediatric Pharmacology and Therapeutics. 2021;26(1):4–20. (This paper describes the various ways melatonin is regulated in different countries and the evidence for its use in children. The United States is the least regulated and there is no evidence supporting the use of US formulations (e.g., OTC supplements) in healthy children at this time. Most studies have been conducted on children with neurodevelopmental comorbidities, which decreases generalizability.)

    Article  Google Scholar 

  35. •• Wei S, Smits MG, Tang X, Kuang L, Meng H, Ni S, et al. Efficacy and safety of melatonin for sleep onset insomnia in children and adolescents: a meta-analysis of randomized controlled trials. Sleep Med. 2020;68:1–8. (This paper is a meta-analysis that sought to evaluate the efficacy and safety of exogenous melatonin as treatment for sleep onset insomnia in a child and adolescent population. Data from seven studies were utilized. Melatonin was found to be effective in treating sleep onset insomnia by advancing dim light melatonin onset, improving sleep onset latency, increasing total sleep time, and advancing sleep onset time. Melatonin was well tolerated, though some adverse events occurred. The adolescent literature was found to be lacking, with only one study included in the meta-analysis.)

    Article  Google Scholar 

  36. Hardeland R. Melatonin, hormone of darkness and more–occurrence, control mechanisms, actions and bioactive metabolites. Cell Mol Life Sci. 2008;65(13):2001–18.

    Article  CAS  Google Scholar 

  37. Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med Rev. 2005;9(1):25–39.

    Article  Google Scholar 

  38. Pandi-Perumal SR, Srinivasan V, Maestroni G, Cardinali D, Poeggeler B, Hardeland R. Melatonin: nature’s most versatile biological signal? FEBS J. 2006;273(13):2813–38.

    Article  CAS  Google Scholar 

  39. Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP. Olcese J International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacological reviews. 2010;62(3):343–80.

    Article  CAS  Google Scholar 

  40. Gooley JJ, Chamberlain K, Smith KA, Khalsa SBS, Rajaratnam SM, Van Reen E, et al. Exposure to room light before bedtime suppresses melatonin onset and shortens melatonin duration in humans. J Clin Endocrinol Metab. 2011;96(3):E463–72.

    Article  CAS  Google Scholar 

  41. Barchas J, Dacosta F, Spector S. Acute pharmacology of melatonin. Nature. 1967;214(5091):919–20.

    Article  CAS  Google Scholar 

  42. Cavallo A, Ritschel WA. Pharmacokinetics of melatonin in human sexual maturation. J Clin Endocrinol Metab. 1996;81(5):1882–6.

    CAS  Google Scholar 

  43. Wirz-Justice A, Armstrong SM. Melatonin: nature’s soporific? J Sleep Res. 1996;5(2):137–41.

    CAS  Google Scholar 

  44. Skene DJ, Arendt J. Human circadian rhythms: physiological and therapeutic relevance of light and melatonin. Ann Clin Biochem. 2006;43(5):344–53.

    Article  CAS  Google Scholar 

  45. Esparham A. Melatonin for kids: what parents should know about this sleep aid [Webpage Article]. Healthy Children; 2022 [Available from: https://www.healthychildren.org/english/healthy-living/sleep/pages/melatonin-and-childrens-sleep.aspx.

  46. Bruni O, Alonso-Alconada D, Besag F, Biran V, Braam W, Cortese S, et al. Current role of melatonin in pediatric neurology: clinical recommendations. Eur J Paediatr Neurol. 2015;19(2):122–33.

    Article  Google Scholar 

  47. Hvolby A, Christensen J, Gasse C, Dalsgaard S, Dreier JW. Cumulative incidence and relative risk of sleep problems among children and adolescents with newly diagnosed neurodevelopmental disorders: a nationwide register-based study. J Sleep Res. 2021;30(3):e13122.

    Article  Google Scholar 

  48. Gringras P, Nir T, Breddy J, Frydman-Marom A. Findling RL Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Am Acad Child Adoles Psychiat. 2017;56(11):948-57. e4.

    Article  Google Scholar 

  49. Schroder CM, Banaschewski T, Fuentes J, Hill CM, Hvolby A, Posserud M-B, et al. Pediatric prolonged-release melatonin for insomnia in children and adolescents with autism spectrum disorders. Expert Opin Pharmacother. 2021;22(18):2445–54.

    Article  CAS  Google Scholar 

  50. Wasdell MB, Jan JE, Bomben MM, Freeman RD, Rietveld WJ, Tai J, et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res. 2008;44(1):57–64.

    CAS  Google Scholar 

  51. Braam W, Didden R, Smits MG, Curfs LM. Melatonin for chronic insomnia in Angelman syndrome: a randomized placebo-controlled trial. J Child Neurol. 2008;23(6):649–54.

    Article  Google Scholar 

  52. Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res. 2012;21(6):700–9.

    Article  Google Scholar 

  53. Gringras P, Gamble C, Jones A, Wiggs L, Williamson P, Sutcliffe A, et al. Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial. BMJ. 2012;345:e6664.

    Article  CAS  Google Scholar 

  54. Mohammadi MR, Mostafavi SA, Keshavarz SA, Eshraghian MR, Hosseinzadeh P, Hosseinzadeh-Attar MJ, et al. Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial. Iran J Psychiatry. 2012;7(2):87.

    Google Scholar 

  55. van der Heijden KB, Smits MG, Van Someren EJ, Ridderinkhof KR, Gunning WB. Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. J Am Acad Child Adolesc Psychiatry. 2007;46(2):233–41.

    Article  Google Scholar 

  56. Malow B, Adkins KW, McGrew SG, Wang L, Goldman SE, Fawkes D, et al. Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord. 2012;42(8):1729–37.

    Article  Google Scholar 

  57. Attenburrow M, Cowen P, Sharpley A. Low dose melatonin improves sleep in healthy middle-aged subjects. Psychopharmacology. 1996;126(2):179–81.

    Article  CAS  Google Scholar 

  58. Hughes RJ, Badia P. Sleep-promoting and hypothermic effects of daytime melatonin administration in humans. Sleep. 1997;20(2):124–31.

    Article  CAS  Google Scholar 

  59. Nagtegaal J, Kerkhof G, Smits M, Van Der Meer Y. Delayed sleep phase syndrome: a placebo-controlled cross-over study on the effects of melatonin administered five hours before the individual dim light melatonin onset. J Sleep Res. 1998;7(2):135–43.

    Article  CAS  Google Scholar 

  60. Waldhauser F, Saletu B, Trinchard-Lugan I. Sleep laboratory investigations on hypnotic properties of melatonin. Psychopharmacology. 1990;100(2):222–6.

    Article  CAS  Google Scholar 

  61. Dahlitz M, Alvarez B, Parkes J, English J, Arendt J, Vignau J. Delayed sleep phase syndrome response to melatonin. The Lancet. 1991;337(8750):1121–4.

    Article  CAS  Google Scholar 

  62. Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab. 2001;86(10):4727–30.

    Article  CAS  Google Scholar 

  63. MacFarlane JG, Cleghorn JM, Brown GM, Streiner DL. The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study. Biol Psychiat. 1991;30(4):371–6.

    Article  CAS  Google Scholar 

  64. Nagtegaal J, Laurant M, Kerkhof G, Smits M, Van der Meer Y, Coenen A. Effects of melatonin on the quality of life in patients with delayed sleep phase syndrome. J Psychosom Res. 2000;48(1):45–50.

    Article  CAS  Google Scholar 

  65. Jockovich M, Cosentino D, Cosentino L, Wears RL, Seaberg DC. Effect of exogenous melatonin on mood and sleep efficiency in emergency medicine residents working night shifts. Acad Emerg Med. 2000;7(8):955–8.

    Article  CAS  Google Scholar 

  66. Jorgensen KM, Witting MD. Does exogenous melatonin improve day sleep or night alertness in emergency physicians working night shifts? Ann Emerg Med. 1998;31(6):699–704.

    Article  CAS  Google Scholar 

  67. Comperatore CA, Lieberman H, Kirby A, Adams B, Crowley J. Melatonin efficacy in aviation missions requiring rapid deployment and night operations. Aviat Space Environ Med. 1996;67(6):520–4.

    CAS  Google Scholar 

  68. Farjallah MA, Hammouda O, Ben Mahmoud L, Graja A, Ghattassi K, Boudaya M, et al. Melatonin supplementation ameliorates oxidative stress, antioxidant status and physical performances recovery during a soccer training camp. Biol Rhythm Res. 2020;51(3):441–52.

    Article  CAS  Google Scholar 

  69. Peck JS, LeGoff DB, Ahmed I, Goebert D. Cognitive effects of exogenous melatonin administration in elderly persons: a pilot study. Am J Geriatr Psychiatry. 2004;12(4):432–6.

    Google Scholar 

  70. Tarokh L, Short M, Crowley SJ, Fontanellaz-Castiglione CE, Carskadon MA. Sleep and circadian rhythms in adolescence. Current sleep medicine reports. 2019;5(4):181–92.

    Article  Google Scholar 

  71. Praninskienė R, Dumalakienė I, Kemežys R, Mauricas M, Jučaitė A. Diurnal melatonin patterns in children: ready to apply in clinical practice? Pediatr Neurol. 2012;46(2):70–6.

    Article  Google Scholar 

  72. Salti R, Galluzzi F, Bindi G, Perfetto F, Tarquini R, Halberg F, et al. Nocturnal melatonin patterns in children. J Clin Endocrinol Metab. 2000;85(6):2137–44.

    Article  CAS  Google Scholar 

  73. Waldhauser F, Frisch H, Waldhauser M, Weiszenbacher G, Zeitlhuber U, Wurtman R. Fall in nocturnal serum melatonin during prepuberty and pubescence. The Lancet. 1984;323(8373):362–5.

    Article  Google Scholar 

  74. Carskadon MA, Acebo C, Richardson GS, Tate BA, Seifer R. An approach to studying circadian rhythms of adolescent humans. J Biol Rhythms. 1997;12(3):278–89.

    Article  CAS  Google Scholar 

  75. Dell’Osso L, Massoni L, Battaglini S, Cremone IM, Carmassi C, Carpita B. Biological correlates of altered circadian rhythms, autonomic functions and sleep problems in autism spectrum disorder. Ann Gen Psychiatry. 2022;21(1):1–28.

    Article  Google Scholar 

  76. Woodford EC, McLay L, France KG, Blampied NM, Gibbs R, Swan CE, et al. Endogenous melatonin and sleep in individuals with Rare Genetic Neurodevelopmental Disorders (RGND): a systematic review. Sleep Med Rev. 2021;57:101433.

    Article  CAS  Google Scholar 

  77. De Leersnyder H. Inverted rhythm of melatonin secretion in Smith-Magenis syndrome: from symptoms to treatment. Trends Endocrinol Metab. 2006;17(7):291–8.

    Article  Google Scholar 

  78. Jan JE, Bax MC, Owens JA, Ipsiroglu OS, Wasdell MB. Neurophysiology of circadian rhythm sleep disorders of children with neurodevelopmental disabilities. Eur J Paediatr Neurol. 2012;16(5):403–12.

    Article  Google Scholar 

  79. Melke J, Botros HG, Chaste P, Betancur C, Nygren G, Anckarsäter H, et al. Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry. 2008;13(1):90–8.

    Article  CAS  Google Scholar 

  80. Jain SV, Horn PS, Simakajornboon N, Beebe DW, Holland K, Byars AW, et al. Melatonin improves sleep in children with epilepsy: a randomized, double-blind, crossover study. Sleep Med. 2015;16(5):637–44.

    Article  Google Scholar 

  81. van Geijlswijk IM, van der Heijden KB, Egberts A, Korzilius HP, Smits MG. Dose finding of melatonin for chronic idiopathic childhood sleep onset insomnia: an RCT. Psychopharmacology. 2010;212(3):379–91.

    Article  Google Scholar 

  82. Wright B, Sims D, Smart S, Alwazeer A, Alderson-Day B, Allgar V, et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. J Autism Dev Disord. 2011;41(2):175–84.

    Article  Google Scholar 

  83. • Szeinberg A, Borodkin K, Dagan Y. Melatonin treatment in adolescents with delayed sleep phase syndrome. Clin Pediatr. 2006;45(9):809–18. (A retrospective study looking at the long-term effects of 3 to 5 mg melatonin administration 2-hours before bedtime as treatment for delayed sleep phase syndrome in children and adolescents ages 10 to 18 years old. Average treatment duration was six months. Comorbidities included attention deficit hyperactivity disorder (ADHD), obstructive sleep apnea, and asthma with associated comedications (e.g., ritalin for those with ADHD). Results showed advanced sleep onset, increased total sleep time, and a decrease in school difficulties. Limitations included reliance on subjective reports, the retrospective nature of the study, and a lack of a placebo control among some procedural issues (e.g., dosage, timing).)

    Article  Google Scholar 

  84. • Sletten TL, Magee M, Murray JM, Gordon CJ, Lovato N, Kennaway DJ, et al. Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: a double-blind, randomised clinical trial. PLoS Med. 2018;15(6):e1002587. (This paper examined the efficacy of 0.5 mg fast-release melatonin given 1 hour before bedtime as treatment for delayed sleep-wake phase disorder in an Australian adult outpatient population utilizing a randomized, placebo-controlled, double-blind clinical trial. Each treatment arm was 4 weeks. Melatonin was found to improve both objective (i.e., actigraphy) and subjective (e.g., Patient Reported Outcomes Measurement Information System [PROMIS]) measurements of sleep.)

    Article  Google Scholar 

  85. •• Eckerberg B, Lowden A, Nagai R, Åkerstedt T. Melatonin treatment effects on adolescent students’ sleep timing and sleepiness in a placebo-controlled crossover study. Chronobiol Int. 2012;29(9):1239–48. (This paper examined the efficacy of 1 mg fast-release melatonin ingested 3 to 4 hours prior to dim light melatonin onset with the hopes of experiencing a circadian phase advance. This study utilized a 5-week crossover design involving a small sample of 21 adolescents. Results demonstrated that chronobiotic melatonin therapy resulted in significantly earlier sleep onset and wake times and less daytime sleepiness. Objective sleep data could not be collected due to equipment malfunction.)

    Article  CAS  Google Scholar 

  86. •• Cheikh M, Hammouda O, Gaamouri N, Driss T, Chamari K, Cheikh RB, et al. Melatonin ingestion after exhaustive late-evening exercise improves sleep quality and quantity, and short-term performances in teenage athletes. Chronobiol Int. 2018;35(9):1281–93. (A randomized controlled trial of a single dose of 10 mg extended release melatonin administered at 10:00 PM on ten adolescent athletes who engaged in vigorous nighttime exercise prior to sleep. Sleep onset latency, total sleep time, sleep efficiency, and number of nighttime awakenings improved. All measurements were completed via polysomnography, which was a methodological strength.)

    Article  CAS  Google Scholar 

  87. •• Cheikh M, Makhlouf K, Ghattassi K, Graja A, Ferchichi S, Kallel C, et al. Melatonin ingestion after exhaustive late-evening exercise attenuate muscle damage, oxidative stress, and inflammation during intense short term effort in the following day in teenage athletes. Chronobiol Int. 2020;37(2):236–47. (This paper examined the effect of a single dose of 10 mg extended release melatonin administered at 10:00 PM on ten adolescent athletes who engaged in vigorous nighttime exercise prior to sleep (reference above). Specifically, melatonin's beneficial effects on oxidative stress and muscle recovery was investigated. Results showed that melatonin ingestion after nighttime exercise reduced oxidative stress and muscle damage.)

    Article  CAS  Google Scholar 

  88. •• Zwart T, Smits M, Egberts T, Rademaker C, van Geijlswijk I, editors. Long-term melatonin therapy for adolescents and young adults with chronic sleep onset insomnia and late melatonin onset: evaluation of sleep quality, chronotype, and lifestyle factors compared to age-related randomly selected population cohorts. Healthcare; 2018: Multidisciplinary Digital Publishing Institute. (This longitudinal paper characterized melatonin usage and sleep outcomes for adolescents and young adults who participated in a randomized controlled trial approximately ten years earlier as pre-pubertal children. The now adolescents and young adults ages 16 to 23 years old reported melatonin usage through adolescence and into early adulthood for an average of 7.1 years. At the ten year follow up, only 9 of the 33 respondents continued to utilize melatonin. Further, participant sleep quality was comparable to age-related controls for all youth regardless of melatonin use, and approximately 75% of respondents were able to maintain normal sleep quality without melatonin treatment.)

  89. •• Saxvig IW, Wilhelmsen-Langeland A, Pallesen S, Vedaa Ø, Nordhus IH, Bjorvatn B. A randomized controlled trial with bright light and melatonin for delayed sleep phase disorder: effects on subjective and objective sleep. Chronobiol Int. 2014;31(1):72–86. (A randomized controlled trial with four parallel treatment arms that aimed to explore the efficacy of 3 mg melatonin with bright light, 3 mg melatonin with dim light, placebo with bright light, and placebo with dim light over the course of two weeks. Participants were between 16 and 25 years old. Results indicated that bedtimes and wake times were advanced after the two-week intervention across all groups with no differences in sleep parameters between groups. Results suggested that the behavioral aspects of the treatment were most effective with no additive effect of neither melatonin nor bright light. Though this study had a relatively small sample size and included young adults, it was methodologically rigorous.)

    Article  CAS  Google Scholar 

  90. Silman R, Leone R, Hooper R, Preece M. Melatonin, the pineal gland and human puberty. Nature. 1979;282(5736):301–3.

    Article  CAS  Google Scholar 

  91. Waldhauser F, Boepple P, Schemper M, Mansfield M, Crowley W Jr. Serum melatonin in central precocious puberty is lower than in age-matched prepubertal children. J Clin Endocrinol Metab. 1991;73(4):793–6.

    Article  CAS  Google Scholar 

  92. Cavallo A. Melatonin and human puberty: current perspectives. J Pineal Res. 1993;15(3):115–21.

    Article  CAS  Google Scholar 

  93. Kennaway D, McCulloch G, Matthews C, Seamark R. Plasma melatonin, luteinizing hormone, follicle-stimulating hormone, prolactin, and corticoids in two patients with pinealoma. J Clin Endocrinol Metab. 1979;49(1):144–5.

    Article  CAS  Google Scholar 

  94. Carr R, Wasdell MB, Hamilton D, Weiss MD, Freeman RD, Tai J, et al. Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders. J Pineal Res. 2007;43(4):351–9.

    Article  CAS  Google Scholar 

  95. Malow BA, Findling RL, Schroder CM, Maras A, Breddy J, Nir T, et al. Sleep, growth, and puberty after two years of prolonged-release melatonin in children with autism spectrum disorder. Journal of the American Academy of Child & Adolescent Psychiatry. 2021.

  96. Olcese JM. Melatonin and female reproduction: an expanding universe. Front Endocrinol. 2020;11:85.

    Article  Google Scholar 

  97. Seabra MdLV. Bignotto M, Pinto Jr LR, Tufik S Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res. 2000;29(4):193–200.

    Article  CAS  Google Scholar 

  98. • Besag F, Vasey MJ, Lao KS, Wong IC. Adverse events associated with melatonin for the treatment of primary or secondary sleep disorders: a systematic review. CNS Drugs. 2019;33(12):1167–86. (A systematic review characterizing the adverse events of 0.15 to 12 mg melatonin administration for sleep disorders. Adverse events included dizziness, headache, daytime sleepiness, hypothermia, palpitations, mood swings, nightmares, agitation, skin irritation, and fatigue, with few of clinical significance. Most adverse events resolved spontaneously. Overall, the safety of melatonin adminstration could not be concluded due to the deficit in data from long-term randomized controlled trials.)

    Article  Google Scholar 

  99. Lelak K, Vohra V, Neuman MI, Toce MS, Sethuraman U. Pediatric melatonin ingestions—United States, 2012–2021. Morb Mortal Wkly Rep. 2022;71(22):725.

    Article  CAS  Google Scholar 

  100. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307–49.

    Article  Google Scholar 

  101. Erland LA, Saxena PK. Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. J Clin Sleep Med. 2017;13(2):275–81.

    Article  Google Scholar 

  102. Organization WH. Adolescent Mental Health 2021 [Available from: https://www.who.int/news-room/fact-sheets/detail/adolescent-mental-health.

  103. Prevention CfDCa. Mental health: poor mental health is a growing problem for adolescents 2021 [Available from: https://www.cdc.gov/healthyyouth/mental-health/index.htm#:~:text=Mental%20Health%20Is%20A%20Growing%20Problem,-chart%20bar%20icon&text=More%20than%201%20in%203,a%2044%25%20increase%20since%202009.

  104. Beebe DW. Cognitive, behavioral, and functional consequences of inadequate sleep in children and adolescents. Pediatr Clin. 2011;58(3):649–65.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychology, Loma Linda University, Loma Linda, CA, USA

    Brooke K. Iwamoto & Tori R. Van Dyk

  2. Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, MLC 301545229-3039, USA

    Kristina M. Decker & Kelly C. Byars

  3. Division of Pulmonary Medicine/Sleep Disorders Center, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, MLC 301545229-3039, USA

    Kelly C. Byars

  4. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA

    Kristina M. Decker & Kelly C. Byars

Authors
  1. Brooke K. Iwamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kristina M. Decker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kelly C. Byars
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tori R. Van Dyk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kelly C. Byars.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article did not involve any human or animal subjects research conducted by the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Sleep and Development

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iwamoto, B.K., Decker, K.M., Byars, K.C. et al. Impact of Exogenous Melatonin on Sleep and Daytime Functioning in Healthy, Typically Developing Adolescents. Curr Sleep Medicine Rep 8, 62–73 (2022). https://doi.org/10.1007/s40675-022-00235-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40675-022-00235-4

Keywords

Search

Navigation